OVERVIEW

Nursing EMPOWER: Personalizing Patient Management through Communication and Education on Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer is organized by Med Learning Group and will be held from Mar 27, 2019 - Mar 27, 2020.

Target Audience:
This CME initiative is designed to meet the educational needs of oncology nurses, nurse practitioners, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Accreditation:
Credit Designation Statement
Med Learning Group designates this online activity for a maximum of 1.5 AMA Category 1 Credit(s)™.

Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with breast cancer. Credits: 1.5 ANCC Contact Hours

Description:
This online activity is focused on the care of patients with early HR positive, HER2-negative breast cancer.

Learning Objectives:
After completing the CME activity, learners should be better able to:
• Describe the unique mechanism of action that CDK 4/6 inhibition provides as oral oncolytic agents in advanced or metastatic HR+/HER2-negative breast cancer
• Review the role of oral CDK 4/6 inhibitors in the treatment of advanced or metastatic breast cancer
• Explore the side-effect profiles of the CDK 4/6 inhibitors and toxicity management in the management of advanced or metastatic HR+/HER2-negative breast cancer
• Review the oncology nurse’s role in the recognition of breast cancer treatment-related adverse events while optimizing patient medication persistence
• Assess ways in which to communicate more openly with patients in order to encourage their engagement across all aspects of their care
• Evaluate current data for decision aids and shared decision-making in optimizing patient and healthcare-team communication and goal-setting

Additional details will be posted as soon as they are available.